Merck KGaA, Darmstadt, Germany has announced plans to acquire SpringWorks Therapeutics for $47 per share in cash, representing an equity value of approximately $3.9 billion. The purchase price offers a 26% premium over SpringWorks' unaffected 20-day volume-weighted average price.
SpringWorks brings two FDA-approved therapies: OGSIVEO® for adult desmoid tumors and GOMEKLI™, the first approved treatment for neurofibromatosis type 1-associated plexiform neurofibromas in adults and children. The acquisition will immediately contribute to Merck's revenues and is expected to be earnings accretive by 2027.
The transaction, funded through available cash and new debt, is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. This strategic move will strengthen Merck's presence in the U.S. market and expand SpringWorks' therapeutic reach globally.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.